Local therapy of stage IV renal cell cancer: a case report

  • Muna Ferner
  • Andrea Vera Keck
  • Dora Niedersüß-Beke
  • Kathrin Strasser-Weippl
case report


This mini-review and case report demonstrates how systemic and local treatments work synergistically for patients with metastatic renal cell carcinoma (mRCC). Although new targeted and immunotherapies have revolutionized the treatment armamentarium of mRCC and dramatically improved patients’ prognosis, local treatment remains an important part of therapy. Here, we report on a patient who benefitted enormously from the combination and interaction of both therapeutic approaches, and we summarize the literature and guidelines that supported our treatment decisions in this case.


Local therapy Metastasectomy Mini-review Targeted and immunotherapy Multidisciplinary 


Compliance with ethical guidelines

Conflict of interest

M. Ferner, A.V. Keck, D. Niedersüß-Beke, and K. Strasser-Weippl declare that they have no competing interests.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMedGoogle Scholar
  2. 2.
    Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):98–102.PubMedGoogle Scholar
  3. 3.
    Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Ulka N, Vaishampayan MD. The role of nephrectomy for kidney cancer in the era of targeted and immune therapies. Am Soc Clin Oncol Educ Book. 2016;35:e16–e20.Google Scholar
  5. 5.
    Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Supplement 5):v58.CrossRefPubMedGoogle Scholar
  6. 6.
    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor—targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014;25(1):149–54.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.CrossRefPubMedGoogle Scholar
  14. 14.
    Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s. c. interferon-alpha and s. c. interleukin-2. Cancer Biother Radiopharm. 2005;20(4):410–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(5):482–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Ornstein MC, Wood LS, Elson P, et al. A phase II study of intermittent Sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2017;35(16):1764–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.CrossRefPubMedGoogle Scholar
  19. 19.
    Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Gibney GT, Aziz SA, Camp RL, et al. c‑Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.CrossRefPubMedGoogle Scholar
  23. 23.
    Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advancedrenal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Muna Ferner
    • 1
  • Andrea Vera Keck
    • 1
  • Dora Niedersüß-Beke
    • 1
  • Kathrin Strasser-Weippl
    • 1
  1. 1.1st Medical Department, Center for Oncology and Hematology & Palliative CareWilhelminenspitalViennaAustria

Personalised recommendations